Ozempic copies for $14 as the generic GLP-1 era starts in India
At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices in the country with the third-largest overweight population. Natco Pharma Ltd. plans to make an injection for semaglutide — the active ingredient in both Ozempic and…

